Overview
- Orforglipron met its main goal in the phase 3 ATTAIN-MAINTAIN study, showing superior weight maintenance versus placebo after 52 weeks following 72 weeks on GLP-1 injections.
- Patients switching from Wegovy maintained prior weight loss with an average difference of 0.9 kilograms, while those switching from Zepbound maintained it with an average difference of 5 kilograms.
- The safety profile matched earlier studies, with mostly mild-to-moderate gastrointestinal events, discontinuations of 4.8% after Wegovy and 7.2% after Zepbound, and no observed liver safety issues.
- Eli Lilly has filed for FDA approval of orforglipron and holds a priority review voucher that could shorten the evaluation period.
- Novo Nordisk’s oral semaglutide could reach the market first, earlier trials showed about 12.4% weight loss on orforglipron versus 16.6% on Novo’s pill, and orforglipron’s non-peptide design avoids dietary dosing restrictions.